Explore original, structured summaries for research and education.
Research profile
Adamax
Adamax is indexed as a Modified heptapeptide derivative research entry. Its current evidence category is Emerging, and published discussion commonly places it within Cognitive, Longevity. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 1,032.24 Da
- Chain length
- 9 amino acids (with modifications)
- Type
- Modified heptapeptide derivative
- Reported half-life
- 8-10 hours
Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AGly-NH2Literature map
Research indications
Cognitive
- Cognitive Enhancementmost effective
- Neuroplasticity Supportmost effective
- Learning and Memorymost effective
Neuroprotective
- Stroke Recoveryeffective
- Oxidative Stress Protectioneffective
- Neuronal Maintenanceeffective
Mood
- Mood Enhancementmoderate
- Anxiety Reductionmoderate
- Stress Resiliencemoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for Adamax. Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of Adamax cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is Adamax approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound)Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. · Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova · 1997
- Semax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound)Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · Brain Research · 2006
- The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound)Gusev EI, Barskov IV, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2018
- The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound)Dergunova LV, Limborska SA, et al. · BMC Genomics · 2014